Synthesis and Characterization of Several Mannich Bases Derived from 2-(4-methylpiperazin-1-yl)acetohydrazide

Abstract

This study explores the transformation of 2-(4-methylpiperazin-1-yl)acetohydrazide (1) through its reaction with phenylisothiocyanate (2), resulting in the formation of a novel urea derivative (3). The synthesis involves an intramolecular ring closure, where the hydrazide functionality plays a crucial role, leading to the formation of a 1,2,4-triazole structure. The journey continues as the 1,2,4-triazole derivative undergoes a Mannich reaction, leveraging its active methylene group. By reacting Compound 3 with formaldehyde and a selection of primary or secondary amines, a β-aminocarbonyl compound is synthesized, showcasing a significant molecular transformation. The structural elucidation of the synthesized compounds is carried out using a range of sophisticated analytical techniques, including mass spectrometry, infrared (IR) spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy for both ¹H and ¹³C nuclei. These methods provide deep insights into the molecular architecture, enabling the determination of atomic connectivity and the identification of functional groups, thus confirming the integrity and structure of the synthesized molecules.

Keywords

• Methylpiperazin
• fluoroquinolone
• mannich base
• 1,2,4-triazole

Ethical Statement

The study is complied with research and publication ethics.

References

1. [1] L. I. Belen’kii, G. A. Gazieva, Y. B. Evdokimenkova, and N. O. Soboleva, “The literature of heterocyclic chemistry, part XVIII,” in Adv. Heterocycl. Chem., E. F. V. Scriven and C. A. Ramsden, Eds. Elsevier, 2020, pp. 385–468.
2. [2] P. T. Acharya, Z. A. Bhavsar, D. J. Jethava, D. B. Patel, and H. D. Patel, “A review on development of bio-active thiosemicarbazide derivatives: Recent advances,” J. Mol. Struct., vol. 1226, p. 129268, 2021.
3. [3] P. Martins et al., “Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine’s toolbox,” Molecules, vol. 20, pp. 16852–16891, 2015.
4. [4] H. Huo, G. Li, B. Shi, and J. Li, “Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids,” Bioorg. Med. Chem., vol. 116882, 2022.
5. [5] M. M. Heravi and S. Sadjadi, “Recent advances in the application of the Sonogashira method in the synthesis of heterocyclic compounds,” Tetrahedron, vol. 65, pp. 7761–7775, 2009.
6. [6] M. Bashir, A. Bano, A. S. Ijaz, and B. A. Chaudhary, “Recent developments and biological activities of N-substituted carbazole derivatives: A review,” Molecules, vol. 20, pp. 13496–13517, 2015.
7. [7] A. R. Shaikh, M. Farooqui, R. Satpute, and S. Abed, “Overview on nitrogen containing compounds and their assessment based on ‘International Regulatory Standards’,” J. Drug Deliv. Ther., vol. 8, pp. 424–428, 2018.
8. [8] T. Qadir, A. Amin, P. K. Sharma, I. Jeelani, and H. Abe, “A review on medicinally important heterocyclic compounds,” The Open Med. Chem. J., vol. 16, 2022.

9. [9] E. Kabir and M. Uzzaman, “A review on biological and medicinal impact of heterocyclic compounds,” Results Chem., vol. 100606, 2022.
10. [10] T. A. Farghaly et al., “Hydrazonoyl halides as precursors for synthesis of bioactive heterocyclic compounds via reaction with aryl- and hetaryl-amine,” Curr. Org. Chem., vol. 27, no. 15, 2022.
11. [11] A. Y. Khormi et al., “Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma,” RSC Adv., vol. 12, no. 42, pp. 27355–27369, 2022.
12. [12] M. S. Saini, A. Kumar, J. Dwivedi, and R. Singh, “A review: Biological significances of heterocyclic compounds,” Int. J. Pharm. Sci. Res., vol. 4, pp. 66–77, 2013.
13. [13] P. V. Thanikachalam, R. K. Maurya, V. Garg, and V. Monga, “An insight into the medicinal perspective of synthetic analogs of indole: A review,” Eur. J. Med. Chem., vol. 180, pp. 562–612, 2019.
14. [14] T. A. Farghaly, W. A. Al-Hasani, M. H. Ibrahim, M. H. Abdellattif, and Z. A. Abdallah, “Design, synthesis, anticancer activity and docking studies of thiazole-linked phenylsulfone moiety as cyclin-dependent kinase 2 (CDK2) inhibitors,” Polycycl. Aromat. Compd., in press, 2022.
15. [15] M. S. Vasava, M. N. Bhoi, S. K. Rathwa, D. J. Jethava, P. T. Acharya, and D. B. Patel, “Benzimidazole: A milestone in the field of medicinal chemistry,” Mini Rev. Med. Chem., vol. 20, pp. 532–565, 2020.
16. [16] M. G. Zayda, A.-A.-H. Abdel-Rahman, and F. A. El-Essawy, “Synthesis and antibacterial activities of different five-membered heterocyclic rings incorporated with pyridothienopyrimidine,” ACS Omega, vol. 5, pp. 6163–6168, 2020.
17. [17] F. Plescia, B. Maggio, G. Daidone, and D. Raffa, “4-(3H)-quinazolinones N-3 substituted with a five-membered heterocycle: A promising scaffold towards bioactive molecules,” Eur. J. Med. Chem., vol. 213, p. 113070, 2021.
18. [18] S. M. Gomha, S. M. Riyadh, T. A. Farghaly, and R. Haggam, “Synthetic utility of bis-aminomercapto[1,2,4] triazoles in the preparation of bis-fused triazoles and macrocycles,” Polycycl. Aromat. Compd., in press, 2022.
19. [19] I. D. H. Elnaggar et al., “Antiproliferative activity of some newly synthesized substituted nicotinamides candidates using pyridine-2(1H) thione derivatives as synthon,” ACS Omega, vol. 7, no. 12, pp. 10304–10316, 2022.
20. [20] M. M. Burbuliene, V. Sakociute, and P. Vainilavicius, “Synthesis and characterization of new pyrimidine-based 1,3,4-oxa (thia) diazole, 1,2,4-triazole and 4-thiazolidinones,” Arkivoc, vol. 12, pp. 281–289, 2009.
21. [21] I. Çapan, S. Servi, I. Yıldırım, and Y. Sert, “Synthesis, DFT Study, Molecular Docking and Drug-Likeness Analysis of the New Hydrazine-1-Carbothioamide, Triazole and Thiadiazole Derivatives: Potential Inhibitors of HSP90,” ChemistrySelect, vol. 6, pp. 5838–5846, 2021.
22. [22] Y. Li, J. Geng, Y. Liu, S. Yu, and G. Zhao, “Thiadiazole – A promising structure in medicinal chemistry,” ChemMedChem, vol. 8, pp. 27–41, 2013.
23. [23] I. Khan et al., “Synthesis, antioxidant activities and urease inhibition of some new 1,2,4-triazole and 1,3,4-thiadiazole derivatives,” Eur. J. Med. Chem., vol. 45, pp. 5200–5207, 2010.
24. [24] S. Sathish Kumar and H. P. Kavitha, “Synthesis and biological applications of triazole derivatives–a review,” Mini-Rev. Org. Chem., vol. 10, pp. 40–65, 2013.
25. [25] O. M. Soltan et al., “Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy,” Eur. J. Med. Chem., vol. 225, p. 113768, 2021.
26. [26] E. N. da Silva Júnior et al., “Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones,” Eur. J. Med. Chem., vol. 179, pp. 863–915, 2019.
27. [27] R. Aggarwal and G. Sumran, “An insight on medicinal attributes of 1,2,4-triazoles,” Eur. J. Med. Chem., vol. 205, p. 112652, 2020.
28. [28] A. H. Malani, A. H. Makwana, and H. R. Makwana, “A brief review article: Various synthesis and therapeutic importance of 1,2,4-triazole and its derivatives,” Moroccan J. Chem., vol. 5, pp. 41–58, 2017.
29. [29] R. V. Veloso et al., “Antioxidant and anti-sickling activity of glucal-based triazoles compounds–An in vitro and in silico study,” Bioorg. Chem., vol. 109, p. 104709, 2021.
30. [30] C. M. Oliphant and G. M. Green, “Quinolones: a comprehensive review,” Am. Fam. Physician, vol. 65, pp. 455–464, 2002.
31. [31] C. Mugnaini, S. Pasquini, and F. Corelli, “The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry,” Curr. Med. Chem., vol. 16, pp. 1746–1767, 2009, doi: 10.2174/092986709788186156.
32. [32] J. M. Blondeau, “Expanded activity and utility of the new fluoroquinolones: a review,” Clin. Ther., vol. 21, pp. 3–40, 1999, doi: 10.1016/S0149-2918(00)88266-1.
33. [33] G. L. Patrick, Antibacterial agents in An Introduction to Medicinal Chemistry. Oxford University Press, Oxford, New York, 2003.
34. [34] P. C. Appelbaum and P. A. Hunter, “The fluoroquinolone antibacterials: past, present, and future perspectives,” Int. J. Antimicrob. Agents, vol. 16, pp. 5–15, 2000, doi: 10.1016/s0924-8579(00)00192-8.
35. [35] P. C. Sharma, A. Jain, and S. Jain, “Fluoroquinolone antibacterials: a review on chemistry, microbiology, and therapeutic prospects,” Acta Pol. Pharm., vol. 66, pp. 587–604, 2009.
36. [36] M. V. De Almeida et al., “Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives,” Bioorg. Med. Chem. Lett., vol. 17, pp. 5661–5664, 2007, doi: 10.1016/j.bmcl.2007.07.073.
37. [37] G. Anquetin et al., “Design, synthesis, and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones,” Eur. J. Med. Chem., vol. 41, pp. 1478–1493, 2006, doi: 10.1016/j.ejmech.2006.07.003.
38. [38] B. A. Cunha, “The fluoroquinolones for urinary tract infections: a review,” Adv. Ther., vol. 11, pp. 277–296, 1994.
39. [39] R. N. Jones, D. E. Low, and M. A. Pfaller, “Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds,” Diagn. Microbiol. Infect Dis., vol. 33, pp. 101–112, 1999, doi: 10.1016/s0732-8893(98)00108-4.
40. [40] D. C. Hooper, “Mechanisms of action and resistance of older and newer fluoroquinolones,” Clin. Infect. Dis., vol. 31, pp. S24–S28, 2000, doi: 10.1086/314056.
41. [41] D. M. Campoli-Richards et al., “Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use,” Drugs, vol. 35, pp. 373–447, 1988, doi: 10.2165/00003495-198835040-00003.
42. [42] K. Drlica et al., “Quinolones: action and resistance updated,” Curr. Top. Med. Chem., vol. 9, pp. 981–998, 2009, doi: 10.2174/156802609789630947.
43. [43] D. C. Hooper, “Emerging mechanisms of fluoroquinolone resistance,” Emerg. Infect. Dis., vol. 7, pp. 337–341, 2001, doi: 10.3201/eid0702.010239.
44. [44] X. Guan et al., “Plasmid-mediated quinolone resistance–current knowledge and future perspectives,” J. Int. Med. Res., vol. 41, pp. 20–30, 2013, doi: 10.1177/0300060513475965.
45. [45] V. Lorian, Antibiotics in Laboratory Medicine, Lippincott Williams & Wilkins, 2005.
46. [46] P. A. Wayne, Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement, Clin. Lab. Standards Inst., M100-S19, 2009.
47. [47] P. A. Wayne, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, vol. 3, pp. 6–12, 2008.
48. [48] Y. J. Zhao, W. Wei, Z. G. Su, and G. H. Ma, “Poly(ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: design, synthesis and biological evaluation,” Int. J. Pharm., vol. 379, pp. 90–99, 2009.
49. [49] O. G. Roman, “Mannich bases in medicinal chemistry and drug design,” Eur. J. Med. Chem., vol. 89, pp. 743–816, 2015.
50. [50] K. Ganiyat, I. E. Willie, and O. Oluwakemi, “Synthesis of Mannich bases: 2-(3-Phenylaminopropionyloxy)-benzoic acid and 3-phenylamino-1-(2, 4, 6-trimethoxy-phenyl)propan-1-one, their toxicity, ionization constant, antimicrobial and antioxidant activities,” Food Chem., vol. 165, pp. 515–521, 2014.
51. [51] T. Fekner et al., “Synthesis of (6S)-cephalosporins from 6-aminopenicillanic acid,” Tetrahedron, vol. 56, pp. 6053–6074, 2000.
52. [52] A. Dassonville-Klimpt et al., “Synthesis and antibacterial activity of catecholate-ciprofloxacin conjugates,” Bioorg. Med. Chem., vol. 22, pp. 4049–4060, 2014.